Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 108Carcinoma, Renal Cell 36Melanoma 13Kidney Neoplasms 13Neoplasm Metastasis 11Urinary Bladder Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Brain Neoplasms 9Sarcoma 8Lung Neoplasms 8Prostate Cancer Metastatic 6Neoplasms 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Prostate Adenocarcinoma 4Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Thyroid Neoplasms 2Spinal Cord Compression 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Osteosarcoma 2Oligometastatic Prostate Cancer 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphatic Metastasis 2Local Recurrence of Malignant Tumor of Prostate 2Colorectal Neoplasms 2Colonic Neoplasms 2

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer Patients with Oligometastases × Radiosurgery × Genitourinary × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡